Theravance Biopharma (TBPH) News Today → Trump’s last act as President (From Porter & Company) (Ad) Free TBPH Stock Alerts $8.44 -0.55 (-6.12%) (As of 04:30 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTheravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024prnewswire.com - April 29 at 6:00 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Down 14.5% in Aprilamericanbankingnews.com - April 29 at 1:50 AMZacks Research Analysts Reduce Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH)marketbeat.com - April 17 at 5:38 PMTheravance Biopharma (TBPH) Price Target Increased by 10.00% to 15.71msn.com - April 17 at 5:14 PMTheravance Biopharma, Inc. (NASDAQ:TBPH) to Post Q1 2026 Earnings of $0.29 Per Share, Zacks Research Forecastsmarketbeat.com - April 16 at 7:44 AMBTIG Research Predicts Over 118% Rally for These 3 Stocksinvestorplace.com - April 15 at 2:19 PMVanguard Group Inc. Sells 379,627 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)marketbeat.com - April 12 at 4:08 AMTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024finance.yahoo.com - April 10 at 8:20 AMTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024prnewswire.com - April 10 at 6:00 AMTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Below Fifty Day Moving Average of $9.04marketbeat.com - March 26 at 5:14 AMEquities Analysts Offer Predictions for Theravance Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:TBPH)marketbeat.com - March 18 at 1:27 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn FY2026 Earnings of $0.75 Per Sharemarketbeat.com - March 15 at 7:48 AMJacobs Levy Equity Management Inc. Has $3.52 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)marketbeat.com - March 15 at 4:15 AMShort-Squeeze Showdown: 3 Stocks Ready to Crush the Skepticsinvestorplace.com - March 12 at 3:59 PMTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn Q1 2024 Earnings of ($0.40) Per Sharemarketbeat.com - March 8 at 6:18 AMAnalyst Reiterates Buy Rating with Increased Price Target Amidst Financial Adjustments and Milestone Payment Potentialmarkets.businessinsider.com - March 7 at 9:55 AMFY2026 EPS Estimates for Theravance Biopharma, Inc. Raised by Leerink Partnrs (NASDAQ:TBPH)marketbeat.com - March 7 at 7:53 AMTheravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic Milestonesmarkets.businessinsider.com - February 28 at 10:50 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 28 at 10:50 AMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatestockhouse.com - February 27 at 11:30 PMTheravance Biopharma Inc (TBPH)investing.com - February 27 at 1:29 PMBalancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharmamarkets.businessinsider.com - February 27 at 1:45 AMTheravance Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $17.6M beats by $0.03Mmsn.com - February 26 at 8:44 PMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateprnewswire.com - February 26 at 4:05 PMTheravance Biopharma Q4 2023 Earnings Previewseekingalpha.com - February 25 at 6:21 PMTheravance Biopharma Stock (NASDAQ:TBPH) Dividends: History, Yield and Datesbenzinga.com - February 24 at 9:19 AMTheravance Biopharma (TBPH) Price Target Increased by 5.77% to 14.03msn.com - February 24 at 9:19 AMTheravance Biopharma to Participate in an Upcoming Investor Conferenceprnewswire.com - February 22 at 6:00 AMWill Theravance Biopharma (NASDAQ:TBPH) Spend Its Cash Wisely?finance.yahoo.com - February 15 at 10:23 AMTheravance Biopharma (NASDAQ:TBPH) Stock Price Passes Below 200-Day Moving Average of $9.83marketbeat.com - February 15 at 3:55 AMTheravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024finance.yahoo.com - February 14 at 8:40 AMTheravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024prnewswire.com - February 14 at 6:00 AMTheravance Biopharma, Inc. (TBPH)finance.yahoo.com - February 1 at 8:21 PMFY2024 EPS Estimates for Theravance Biopharma, Inc. Lifted by Zacks Research (NASDAQ:TBPH)marketbeat.com - January 29 at 2:21 AMAnalysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before Longfinance.yahoo.com - January 19 at 10:13 AMDown -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaroundfinance.yahoo.com - January 12 at 2:00 PMBuy Rating Upheld for Theravance Biopharma Amid Confidence in Yupelri and Pipeline Potentialmarkets.businessinsider.com - January 9 at 9:32 AMTheravance Biopharma (NASDAQ:TBPH) Downgraded by Evercore ISImarketbeat.com - January 8 at 8:51 AMTheravance Biopharma downgraded at Evercore ISI after Yupelri trial failurerealmoney.thestreet.com - January 6 at 2:05 PMEvercore ISI gets more bearish on Theravance Biopharma, downgrades sharesrealmoney.thestreet.com - January 6 at 1:14 AMWhy Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today?msn.com - January 5 at 3:09 PMTheravance Biopharma Study For Yupelri Misses Primary Endpointmarketwatch.com - January 5 at 10:08 AMTheravance drops as late-stage trial for COPD therapy Yupelri failsmsn.com - January 5 at 10:08 AMTheravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)finance.yahoo.com - January 5 at 10:08 AMSG Americas Securities LLC Acquires 101,475 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)marketbeat.com - December 28 at 4:53 AMTheravance Biopharma in Cooperation Agreement With Irenic Capitalmarketwatch.com - December 21 at 10:47 PMTheravance Biopharma signs cooperation agreement with Irenic Capitalmsn.com - December 21 at 5:47 PMTheravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directorsfinance.yahoo.com - December 21 at 5:47 PMTheravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conferencefinance.yahoo.com - December 18 at 8:40 AMTheravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?finance.yahoo.com - December 7 at 3:29 PM Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s last act as President (Ad)You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. For the full story, click here. TBPH Media Mentions By Week TBPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TBPH News Sentiment▼0.960.34▲Average Medical News Sentiment TBPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TBPH Articles This Week▼31▲TBPH Articles Average Week Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: STTK News SLRN News IGMS News TVTX News ANL News FULC News TRDA News APLT News KALV News CDMO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TBPH) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss RatingsTruth about Trump you’ve never heardPorter & CompanyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmith4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
